TLPH Talphera (TLPH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001427925
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter
Talphera insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for TALPHERA, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Feb 12, 2026.
- -17.1% median (-13.5% mean) 90-day return after 8 previous buys.
- The trade is 26.6% of the 800,705 shares held after it.
- 3 other insiders bought within 30 days.
- 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought about $125.9K of TLPH on Mar 13, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Apr 2, 2025.
- -19.1% median (-17.0% mean) 90-day return after 7 previous buys.
- The trade is 18.0% of the 586,954 shares held after it.
- 3 other insiders bought within 30 days.
- 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought about $85.3K of TLPH on Feb 12, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 14, 2024.
- -10.6% median (-10.6% mean) 90-day return after 2 previous buys.
- The trade is 42.1% of the 83,178 shares held after it.
- 3 other insiders bought within 30 days.
- 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Aslam Shakil bought about $28.4K of TLPH on Feb 12, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 45.9% of the 76,230 shares held after it.
- 3 other insiders bought within 30 days.
- 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Engineering Officer Dasu Badri N bought about $28.4K of TLPH on Feb 12, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 2, 2024.
- The trade is 49.3% of the 91,256 shares held after it.
- 3 other insiders bought within 30 days.
- 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer ASADORIAN RAFFI bought about $36.5K of TLPH on Feb 12, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.15 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.9% of the float short (float per yahoo 2026-10-26) · 6.3 days to cover · settled 2026-09-30
below 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TLPH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.4%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TLPH: institutional holders (13F)
13F holdings, latest reported quarter
6,985,038 sh
$7.2M
5,169,501 sh
$5.3M
4,601,502 sh
$4.7M
3,589,186 sh
$3.7M
1,774,962 sh
$1.8M
Congress trades in TLPH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TLPH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TLPH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$453.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$170.4K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$13.4K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$42.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$51.7K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$269.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Angotti
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.1M
$1.5M
$691.1K
-50%
n/a
2024
$1.0M
$844.6K
$642.9K
-77%
n/a
2023
$1.2M
$1.0M
$778.4K
-67%
n/a
2022
$1.3M
$692.5K
$788.8K
-80%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TLPH financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TLPH
| FY Dec 2025 | $28.0K |
| FY Dec 2024 | $0 |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $1.8M |
| FY Dec 2021 | $2.8M |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $1.0K |
| Jun 2025 | $0 |
| Mar 2025 | $27.0K |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM TLPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +2,696% |
| FY Dec 2021 | -1,246% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TLPH
| FY Dec 2025 | -$11.4M |
| FY Dec 2024 | -$12.7M |
| FY Dec 2023 | -$17.6M |
| FY Dec 2022 | -$28.7M |
| FY Dec 2021 | -$31.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$2.3M |
| Sep 2024 | -$2.9M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2022-12-31 (42 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity TLPH
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.25x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt TLPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -5.28x |
| FY Dec 2021 | -2.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-143.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TLPH
| FY Dec 2025 | -114.2% |
| FY Dec 2024 | -117.7% |
| FY Dec 2023 | -102.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -143.4% |
| Mar 2026 | -118.4% |
| Dec 2025 | -114.2% |
| Sep 2025 | -86.0% |
| Jun 2025 | -116.8% |
| Mar 2025 | -106.2% |
| Dec 2024 | -117.7% |
| Sep 2024 | -112.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-69.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TLPH
| FY Dec 2025 | -59.6% |
| FY Dec 2024 | -67.3% |
| FY Dec 2023 | -54.2% |
| FY Dec 2022 | +76.2% |
| FY Dec 2021 | -48.7% |
| Jun 2026 | -69.6% |
| Mar 2026 | -63.1% |
| Dec 2025 | -59.6% |
| Sep 2025 | -47.9% |
| Jun 2025 | -54.7% |
| Mar 2025 | -53.2% |
| Dec 2024 | -67.3% |
| Sep 2024 | -70.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital TLPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-80.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TLPH
| FY Dec 2025 | -65.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -33.5% |
| Jun 2026 | -80.8% |
| Mar 2026 | -74.2% |
| Dec 2025 | -65.0% |
| Sep 2025 | -56.9% |
| Jun 2025 | -75.3% |
| Mar 2025 | -72.5% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing TLPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$55.8M
market value at close 2026-10-27 on 2026-08-06 shares, plus long-term 2022-12-31 (42 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value TLPH
| FY Dec 2025 | $47.2M |
| FY Dec 2024 | -$7.8K |
| FY Dec 2023 | $6.8M |
| FY Dec 2022 | $6.9M |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $52.7M |
| Mar 2026 | $33.7M |
| Dec 2025 | $47.2M |
| Sep 2025 | $14.8M |
| Jun 2025 | $2.6M |
| Mar 2025 | $3.2M |
| Dec 2024 | -$7.8K |
| Sep 2024 | $3.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-21.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield TLPH
| FY Dec 2025 | -21.4% |
| FY Dec 2024 | -143.2% |
| FY Dec 2023 | -140.2% |
| FY Dec 2022 | -170.4% |
| FY Dec 2021 | -2.4% |
| Jun 2026 | -23.0% |
| Mar 2026 | -30.1% |
| Dec 2025 | -21.4% |
| Sep 2025 | -61.2% |
| Jun 2025 | -123.1% |
| Mar 2025 | -155.2% |
| Dec 2024 | -143.2% |
| Sep 2024 | -98.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing TLPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $28.0K | $0 | $651.0K | $1.8M |
| Operating income | -$13.5M | -$15.3M | -$16.9M | -$25.3M |
| Net income | -$14.3M | -$13.0M | -$18.4M | $47.8M |
| EPS (diluted) | n/a | n/a | -1.29 | 5.72 |
| Operating cash flow | -$11.4M | -$12.7M | -$17.5M | -$28.3M |
| Cash | $5.9M | $8.9M | $5.7M | $15.3M |
| Long-term debt | n/a | n/a | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
TLPH Stock Sonar score 4/7 axes
Find similar shapesCompareTLPH ranks highest on financial health (99th percentile) and risk and compliance (61st), and lowest on profitability (30th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
